Reitan Colleen F
Reitan Colleen F's purchase track record
Reitan Colleen F has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/17/2024 | ALNY | $1K | -16.0% | -21.0% | -9.6% |
| 8/29/2024 | ALNY | $9K | -11.8% | -17.4% | +4.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets. Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.
Transaction History
| MYGN | ▲ Buy | Grant | 59,701 | $0 | 6/4/2026 | View on chart |
| ALNY | ▲ Buy | Grant | 671 | $0 | 5/20/2026 | View on chart |
| ALNY | ▲ Buy | Option Exercise | 18,000 | $1.8M | 9/9/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,645 | $752K | 9/9/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,888 | $866K | 9/9/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,403 | $645K | 9/9/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 473 | $218K | 9/9/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 972 | $463K | 9/9/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,183 | $565K | 9/9/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,450 | $694K | 9/9/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,386 | $665K | 9/9/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 25 | $12K | 9/9/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 2,290 | $1.1M | 9/9/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,652 | $765K | 9/9/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 799 | $371K | 9/9/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 222 | $105K | 9/9/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 823 | $389K | 9/9/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 838 | $397K | 9/9/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 951 | $452K | 9/9/2025 | View on chart |
| MYGN | ▲ Buy | Grant | 49,796 | $0 | 6/5/2025 | View on chart |
| ALNY | ▲ Buy | Grant | 775 | $0 | 5/8/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 36 | $8K | 4/16/2025 | View on chart |
| ALNY | ▲ Buy | Open Market | 4 | $1K | 10/17/2024 | View on chart |
| MYGN | ▼ Sell | Open Market | 46,012 | $1.3M | 9/3/2024 | View on chart |
| ALNY | ▲ Buy | Open Market | 32 | $9K | 8/29/2024 | View on chart |
| MYGN | ▲ Buy | Grant | 15,695 | $0 | 6/6/2024 | View on chart |
| MYGN | ▲ Buy | Grant | 15,151 | $0 | 6/1/2023 | View on chart |
| MYGN | ▲ Buy | Grant | 17,275 | $0 | 6/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis
An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis. An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.